All In Biotech

Free tool

FAERS Monitor: Ohtuvayre

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 217389 or its brand name (Ohtuvayre, Ensifentrine). Reports on generic versions are filed under their own applications.

Reports

1,830

Serious

635

35% of reports

Hospitalization

343

Death reported

73

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea376
  • drug ineffective132
  • chronic obstructive pulmonary disease129
  • diarrhoea106
  • cough99
  • back pain98
  • pneumonia94
  • product dose omission issue91
  • no adverse event83
  • death82
  • headache75
  • chest discomfort63
  • incorrect dose administered59
  • productive cough55
  • fatigue54

Reports by year received

View as table
YearReports
20202
20215
20223
20232
202427
2025783
20261,008

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,329 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
chronic obstructive pulmonary diseaseSignal12928.524.13,393
productive coughSignal5513.310.2612
dyspnoeaSignal3767.67.02,221
chest discomfortSignal637.15.5324
no adverse eventSignal835.34.3285
back painSignal984.84.0299
coughSignal994.13.4228
product dose omission issueSignal913.62.9167
pneumoniaSignal943.32.7154
incorrect dose administeredSignal593.02.376
diarrhoea1061.91.645
headache751.41.18
drug ineffective1321.21.03
death821.10.91
fatigue540.80.63

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.